Machine learning meets multi-omics for precision medicine

May 23 2022

Scailyte's 5th anniversary Mini-symposium - Machine learning meets multi-omics for precision medicine

Date: 14.06.2022

Format: Online with panel discussions

Videos: https://www.youtube.com/playlist?list=PL0OpIB3Hq3EOCz-r1MU81McrpFFYPdVgW

Precision medicine, multi-omics & machine learning, Dr Peter Nestorov, CEO, Scailyte

Multi-omics in Industry by Dr Jonathan Scolnick, General Manager of Singleron Singapore

Identifying New Pathogenic T Cells by Prof Michael Brenner, Harvard Medical School

Simultaneous analysis of millions of individual cells empowered with machine learning has potential to revolutionize treatments of many challenging human diseases including cancer, inflammatory and neurological disorders.

Biology has become a data science. For instance, recent single-cell profiling technologies are capable of measuring thousands of variables for each of hundreds of thousands to millions of cells in a single sample. Machine learning models are beginning to provide significant improvements in extracting information sensitively and with speed from such datasets which are often high-dimensional, sparse, and complex. Consequently, last year has seen enormous advances in deep learning applications in a variety of single-cell omics assays including genomics, transcriptomics, proteomics, metabolomics and multi-omics integration. It is highly timely to discuss the potential impact of insights generated by multi-omics machine learning platforms on the patient journey, clinical research and wider pharmaceutical sector through this miniconference.

We will cover examples and potential applications of deep learning on single-cell and other high throughput datasets in the context of:

Early diagnosis
Differential diagnosis against overlapping etiologies
Patient stratification for therapy
Design of clinical trials
Understanding disease mechanisms
Drug discovery and repurposing
Lifestyle decisions

Target audience:

Drug developers advancing precision medicine and biomarker-driven science
Industry and academic partners running clinical trials
Bioinformaticians and data scientists in academia and healthcare industries interested in machine learning approaches for multi-omics data
Scientists interested in advancing biological understanding of disease and target identification with machine learning, single-cell and other multidimensional data

Programme:

Virtual: Zoom; all Times indicated are CET Times, Lines to open at 14:20 CET time.

TALKS:

14:30 –14:40 Welcome and objectives; Peter Nestorov, CEO, Scailyte

14:40 –15:00 Machine learning on Multiomics

Christopher Yau, Professor of Artificial Intelligence at the University of Oxford and Fellow at the Alan Turing Institute, UK

15:00 –15:20 Multiomics in industry I

Asif Jan, Chief Data Officer, Owkin

15:20 –15:40 Clinical applications of Multiomics

Michael Brenner, Elizabeth Fay Brigham Professor of Medicine at Harvard Medical School, USA

15:40 –16:00 Multiomics in industry II

Philippe Menu, Chief Medical Officer, Sophia Genetics

16:00 –16:20 Break

BRAINSTORMING SESSIONS:

16:20 –16:50 Parallel session I (Translating Multiomics discoveries into applications for Pharma industry and Clinic)

Panel members: Industry: Dr. Philippe Menu (Sophia Genetics), Dr. Marcus Otte (Merck), Dr. Miguel Edwards (DeciBio); Academia: Prof. Michael Brenner (Harvard Medical School), Prof. Marco Ruella (University of Pennsylvania), Prof. Woongyang Park (Sungkyunkwan University, Samsung Genome Institute and Geninus); Dr Diana Stoycheva (moderator, Scailyte)

16:20 –16:50 Parallel session II (Data Science solutions and future prospects for Multiomics and machine learning)

Panel members: Industry: Dr. Asif Jan (Owkin), Academia: Prof. Christopher Yau (University of Oxford); Dr. Kieran Campbell (University of Toronto), Dr. Dennis Göhlsdorf (Scailyte); Sarah Carl (moderator, Scailyte)

16:50 –17:00 Concluding remarks, Corinne Solier, COO, Scailyte

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets.

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Meet Scailyte at BioTechX

Meet Scailyte at BioTechX at Booth #37 in Basel Congress Center from 8th to 10th November 2022.

Scailyte closes Series A funding with a CHF 6 million investment

Scailyte has successfully finished the Series A funding raising CHF 6 million from a Swiss family of

VACANCY: Internship in Women’s Health R&D

The internship in Women’s Health R&D will focus on our in vitro diagnostics development work in en

Nilogen and Scailyte Are Joining Forces to Find the “Right” Treatment for Every Patient

Nilogen and Scailyte are joining forces to increase the success of cancer therapies in clinics and t